| 1 |
34551970 | Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma. | 2022 Feb |
1 |
| 2 |
33721621 | Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. | 2021 Apr |
4 |
| 3 |
33725154 | Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. | 2021 Aug |
1 |
| 4 |
33923880 | Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib. | 2021 Apr 20 |
2 |
| 5 |
33929994 | Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia. | 2021 Oct 1 |
2 |
| 6 |
34981062 | Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice. | 2021 Dec 20 |
1 |
| 7 |
31521657 | Molecular dynamics simulation and 3D-pharmacophore analysis of new quinoline-based analogues with dual potential against EGFR and VEGFR-2. | 2020 Jan 1 |
1 |
| 8 |
32336008 | A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. | 2020 Aug |
1 |
| 9 |
32800552 | Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma. | 2020 Oct 20 |
2 |
| 10 |
31299389 | Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment. | 2019 Sep |
2 |
| 11 |
28842826 | Environmental Enrichment Reverses Tyrosine Kinase Inhibitor-Mediated Impairment Through BDNF-TrkB Pathway. | 2018 Jan |
2 |
| 12 |
29787277 | Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. | 2018 Jul 2 |
1 |
| 13 |
30555244 | Vandetanib (ZD6474) induces antiangiogenesis through mTOR-HIF-1 alpha-VEGF signaling axis in breast cancer cells. | 2018 |
4 |
| 14 |
26986978 | Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. | 2017 Aug |
1 |
| 15 |
28132823 | Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies. | 2017 Apr 1 |
2 |
| 16 |
28259610 | Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. | 2017 Apr |
1 |
| 17 |
29086823 | Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation. | 2017 May 30 |
2 |
| 18 |
26578684 | KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. | 2016 Apr 15 |
1 |
| 19 |
27429741 | Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade. | 2016 |
2 |
| 20 |
25503302 | Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. | 2015 Feb |
1 |
| 21 |
25676691 | VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner. | 2015 Apr 28 |
2 |
| 22 |
25910950 | A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. | 2015 Aug 15 |
2 |
| 23 |
26050198 | ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib. | 2015 Aug 28 |
1 |
| 24 |
26170630 | Selective use of vandetanib in the treatment of thyroid cancer. | 2015 |
1 |
| 25 |
26579488 | Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study. | 2015 Jun |
2 |
| 26 |
24502390 | Vandetanib for the treatment of thyroid cancer: an update. | 2014 Mar |
1 |
| 27 |
24671507 | A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer. | 2014 Aug |
3 |
| 28 |
24709487 | Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. | 2014 Jun |
1 |
| 29 |
24927771 | Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. | 2014 Sep |
2 |
| 30 |
24970912 | A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor. | 2014 Sep |
2 |
| 31 |
25089348 | Vandetanib as a potential treatment for breast cancer. | 2014 Sep |
1 |
| 32 |
25117183 | Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine. | 2014 Sep |
2 |
| 33 |
23202050 | Vandetanib and the management of advanced medullary thyroid cancer. | 2013 Jan |
1 |
| 34 |
23231950 | Vandetanib for the treatment of medullary thyroid cancer. | 2013 Feb 1 |
1 |
| 35 |
23436052 | MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma. | 2013 Jul |
1 |
| 36 |
23584948 | Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. | 2013 Oct |
2 |
| 37 |
23799852 | Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma. | 2013 Jul 9 |
2 |
| 38 |
24005613 | Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). | 2013 Dec |
1 |
| 39 |
24089699 | Specific binding of modified ZD6474 (Vandetanib) monomer and its dimer with VEGF receptor-2. | 2013 Nov 20 |
5 |
| 40 |
22075979 | Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296. | 2012 Feb |
2 |
| 41 |
22158569 | Vandetanib for the treatment of thyroid cancer. | 2012 Jan |
2 |
| 42 |
22184381 | Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. | 2012 Feb 10 |
1 |
| 43 |
22206795 | Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. | 2012 Jan |
1 |
| 44 |
22245891 | Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. | 2012 May |
2 |
| 45 |
22307735 | Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. | 2012 Sep |
1 |
| 46 |
22343387 | Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. | 2012 May |
4 |
| 47 |
22429581 | [Vandetanib for advanced non-small cell lung cancer: a meta-analysis]. | 2012 Mar |
2 |
| 48 |
22484209 | Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. | 2012 Aug 15 |
1 |
| 49 |
22667325 | Vandetanib for the treatment of lung cancer. | 2012 Aug |
1 |
| 50 |
22701615 | Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. | 2012 |
1 |